arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ASSEMBLY BIOSCIENCES, INC.

ASMB
$20.00 ▲ +0.21 (+1.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

ASSEMBLY BIOSCIENCES, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $377.1M
Dividend Yield —
Revenue Growth 38.9% ↗
Op. Margin -47.4% ↗
ROIC -1.6% ↗
FCF / Share $-0.82 ↗
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.37M
↑ +38.9% —
Net Income Profit after all expenses
$-3.86M
↑ +62.2% —
Operating Margin Operating profit as % of sales
-47.4%
↑ +65.7% 11th
FCF / Share Free cash flow per share
$-0.82
↑ +37.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns ↑
40
Cash Quality ↑
97

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 71 quarters